Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpFinancial_Report.xls
10-Q - FORM 10-Q - Raptor Pharmaceutical Corpd270609d10q.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR8.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR6.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR2.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR9.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR3.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR7.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR1.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR12.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR18.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR11.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR17.htm
EX-32.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D. AND KIM R. TSUCHIMOTO - Raptor Pharmaceutical Corpd270609dex321.htm
EX-31.2 - CERTIFICATION OF KIM R. TSUCHIMOTO, CHIEF FINANCIAL OFFICER - Raptor Pharmaceutical Corpd270609dex312.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR14.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR13.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR19.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR10.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR15.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR16.htm
XML - IDEA: XBRL DOCUMENT - Raptor Pharmaceutical CorpR4.htm
EX-31.1 - CERTIFICATION OF CHRISTOPHER M. STARR, PH.D., CHIEF EXECUTIVE OFFICER - Raptor Pharmaceutical Corpd270609dex311.htm
v2.4.0.6
Condensed Consolidated Statement Of Stockholders' Equity (Deficit) (USD $)
Common Stock [Member]
Additional Paid- In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Deficit Accumulated During Development Stage [Member]
Total
Balance at Aug. 31, 2011 $ 35,569 $ 73,817,083 $ 1,904 $ (78,001,604) $ (4,147,048) [1]
Balance, shares at Aug. 31, 2011 35,569,188        
Exercise of common stock warrants 687 1,956,252     1,956,939
Exercise of common stock warrants,shares 686,815        
Exercise of common stock options 17 39,674     39,691
Exercise of common stock options, shares 17,485        
Employee stock-based compensation expense   916,738     916,738
Reclassification of the fair value of warrant liabilities upon exercise   2,375,843     2,375,843
Issuance of common stock in a follow-on public offering at $4.00 per share purchase price, net of fundraising costs totaling $3,166,146 11,500 42,822,354     42,833,854
Issuance of common stock in a follow-on public offering at $4.00 per share purchase price, net of fundraising costs totaling $3,166,146, shares 11,500,000        
Foreign currency translation gain     (8,473)   (8,473)
Net Loss       (11,432,857) (11,432,857)
Balance at Nov. 30, 2011 $ 47,773 $ 121,927,944 $ (6,569) $ (89,434,461) $ 32,534,687
Balance, shares at Nov. 30, 2011 47,773,488        
[1] Derived from the Company's audited consolidated financial statements as of August 31, 2011.